Evercore ISI analyst Joshua Schimmer downgraded Seagen (SGEN) to In Line from Outperform with a price target of $229, up from $175, after Pfizer (PFE) announced a deal to acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN: